更新于：2024-12-26
Betamethasone Sodium Phosphate
磷酸钠倍他米松
更新于：2024-12-26
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C22H30FNa2O8P |
InChIKeyODEOTKLZVXBMJD-LWCNAHDDSA-N |
CAS号151-73-5 |
关联
18
项与 磷酸钠倍他米松 相关的临床试验Efficacy of Intramuscular Glucocorticoid Injection in Patients With Lumbar Radicular Pain
Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy (PRE-EASE)
Timing of Late Preterm Corticosteroid Administration and Neonatal Hypoglycemia
100 项与 磷酸钠倍他米松 相关的临床结果
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的转化医学
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的专利（医药）
登录后查看更多信息
428
项与 磷酸钠倍他米松 相关的文献（医药）2025-03-01FOOD CHEMISTRY
Elucidation of the relationship between milk protein–stevioside interactions and interfacial layer properties based on multi-spectroscopy and interfacial rheology
Article
作者: Wei, Zihao ; Xue, Changhu ; Jin, Ziheng ; Li, Yujin ; Wang, Meng
The intricate interactions between stevioside (STE) and milk protein (mixtures of whey protein isolate and sodium caseinate, WPI/SC) as well as interfacial stabilization mechanisms were investigated. At the molecular scale, it was observed that the incorporation of the steviol hydrophobic skeleton enhanced the surface hydrophobicity of WPI/SC (from 1560.73 to 2175.63), favoring the reduction of the energy barrier for adsorption. At the mesoscopic scale, the analysis of adsorption kinetics and interfacial dilatational rheological response revealed that STE and WPI/SC had a synergistic effect on the attenuation of oil-water interfacial tension, with the lowest value of interfacial tension of 9.46 mN/m. Meanwhile, at low concentrations of STE, the WPI/SC-STE complexes unfolded and self-assembled at the interface to form a spring-like interfacial layer that relaxed in response to external deformation. In contrast, at high concentrations of STE, it gradually replaced WPI/SC-STE complexes at the interface and destabilized the interfacial layer.
2025-02-01CARBOHYDRATE POLYMERS
Intervention mechanism of amphiphilic natural sweeteners on starch chain dynamic behavior: Computational and experimental insights
Article
作者: Lu, Baiyi ; Wang, Fan ; Shen, Jianfu
Amphiphilic natural sweeteners (i.e. steviol glycosides (STE) and glycyrrhizic acid (GA)) have been adopted to improve the quality of various starchy products, which can fundamentally be characterized as the intervention of the former in the chain dynamic behavior of the latter. However, these phenomena and related mechanisms still lack systematic insights. Herein, dual-temperature molecular dynamic simulations combined with experimental analysis were used to tandemly investigate the intervention of sweeteners in six types of chain dynamic behaviors that are strongly correlated with starch properties, including unwinding, movement, long/short-term reassociation, rearrangement, and depolymerization. The results show that STE and GA both promoted the chain unwinding and movement, and also retarded the chain short/long-term reassociation and rearrangement. Besides, GA exhibited a greater role than STE in facilitating chain unwinding and movement. Peculiarly, GA (0 %-40 % w/w) collaborated with starch to form a new microstructure, especially at high content (≥ 20 % w/w), which endowed starch with exceptionally high hardness (15.50 gf→189.36 gf) and hardening rate (2.72 gf/d→17.76 gf/d), and also placed a physical barrier to retard starch depolymerization (slowly digestible starch: 11.26 %→20.62 %). This work contributes data and theoretical support for the development of starch/amphiphilic natural sweetener composite matrices.
2024-12-31RENAL FAILURE
Efficacy and safety of nine immunosuppressive agents for primary focal segmental glomerulosclerosis in adults: a pairwise and network meta-analysis
Review
作者: Zhu, Yan ; Chen, Bo ; Xu, Gaosi
BACKGROUND:
Immunosuppressants are widely used as the preferred treatment for primary focal segmental glomerulosclerosis (pFSGS). Nevertheless, controversies persist regarding the effectiveness and side effects of different immunosuppressive medications.
METHODS:
From July 2023 until June 2024, we systematically searched PubMed, Cochrane Library, Web of Science, clinicalrials.gov, SinoMed, Chinese Biomedical, Chinese National Knowledge Infrastructure, Wanfang, and VIP information. Randomized controlled trials comparing different immunosuppressants were included in adult patients with pFSGS, with total remission (TR) and 24-h urine total protein (24-h UTP) as the main outcome measures.
RESULTS:
We identified 20 RCTs comparing nine different immunosuppressants for the final analysis. Most immunosuppressants showed better therapeutic effects in TR compared to non-immunosuppressive therapies (NIT), with risk ratios (RRs) of 2.22 (95% CI 1.41-3.50) for cyclosporin, 2.10 (1.57-2.80) for leflunomide-combined steroids, 2.01 (1.24-3.27) for chlorambucil-combined steroids, 1.98 (1.17-3.33) for tacrolimus-combined steroids, 1.89 (1.36-2.63) for cyclosporin-combined steroids, 1.67 (1.28-2.18) for mycophenolate mofetil-combined steroids, and 1.47 (1.21-1.80) for steroids. Only mycophenolate mofetil-combined steroids (SMD -11, 95% CI -21 to -0.64) showed significant superiority in reducing 24-h UTP when compared with NIT. The subgroup analyses of steroids-resistant nephrotic syndrome (SRNS) patients showed that CSA + STE was significantly superior than the NIT group, with RR of 10.5 (95% CI 2.28-44.35).
CONCLUSION:
Steroids remain the recommended initial treatment for pFSGS. For those patients with SRNS, CSA + STE might be the best choice for improving the rate of TR. LEF + STE and MMF + STE also appear to offer a steroid-saving alternative to high-dose glucocorticoids for patients.
100 项与 磷酸钠倍他米松 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 溃疡性结肠炎 | 日本 | 1992-03-13 | |
| 克罗恩病 | 日本 | 1992-03-13 | |
| 睑缘炎 | 日本 | 1985-11-20 | |
| 结膜炎 | 日本 | 1985-11-20 | |
| 角膜炎 | 日本 | 1985-11-20 | |
| 耳炎 | 日本 | 1985-11-20 | |
| 炎症 | 美国 | 1974-12-31 | |
| 胶原蛋白疾病 | 日本 | 1973-01-31 | |
| 内分泌系统疾病 | 日本 | 1973-01-31 | |
| 心脏衰竭 | 日本 | 1973-01-31 | |
| 肾病综合征 | 日本 | 1973-01-31 | |
| 类风湿关节炎 | 日本 | 1973-01-31 | |
| 眼部炎症 | 日本 | 1964-10-07 | |
| 外耳炎 | 日本 | 1964-10-07 | |
| 中耳炎 | 日本 | 1964-10-07 | |
| 过敏性鼻炎 | 日本 | 1964-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | (Bupivacaine Hydrochloride and Betamethasone Sodium Phosphate) | 鬱齋觸鏇築壓積衊顧廠(糧鏇製壓襯簾願鑰構醖) = 窪淵鹽襯襯夢膚簾構願 衊鬱壓願觸衊醖簾繭簾 (糧獵簾淵衊製窪構衊積, 選淵鏇窪觸鬱簾糧顧範 ~ 壓鹽醖糧簾願艱簾選夢) 更多 | - | 2020-11-02 | ||
(Bupivacaine Hydrochloride) | 鬱齋觸鏇築壓積衊顧廠(糧鏇製壓襯簾願鑰構醖) = 鑰網觸願積艱醖壓窪夢 衊鬱壓願觸衊醖簾繭簾 (糧獵簾淵衊製窪構衊積, 齋鏇廠鏇夢構蓋壓鑰夢 ~ 顧築簾積齋築遞鬱繭顧) 更多 | ||||||
N/A | 糖尿病 blood glucose levels | 5 | 糧遞積衊齋鹽鑰簾範壓(繭憲糧蓋製夢鹹膚壓鏇) = 網選襯範窪選鏇簾膚願 繭蓋醖襯觸醖選壓鑰願 (艱廠蓋遞衊獵願範顧繭 ) | 积极 | 2009-06-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用